BOFA Securities: The target price of Tianjin Takeda Pharmaceutical (03347.HK) raised to HK$56, reiterates "buy" rating.

According to the Zhtng Cijng app, Bank of America Securities released a research report stating that Taidoc Medicine (03347.HK) second quarter total revenue increased by 7.8% to 1.686 billion yuan, total gross profit increased by 8.2% to 508 million yuan, gross profit margin increased by 0.1 percentage point to 30.1%, and net loss was 129 million yuan. The bank lowered Taidoc Medicine's revenue forecast for 2025 to 2027 by 10%, while raising its target price from 40.6 Hong Kong dollars to 56 Hong Kong dollars, reiterating a "buy" rating.